BioMed Research International

Perinatal Pharmacology


Publishing date
31 Jan 2014
Status
Published
Submission deadline
18 Oct 2013

1Department of Development and Regeneration, KU Leuven and Neonatal Intensive Care Unit, University Hospitals Leuven, Belgium

2Department of Surgery, Section of Neonatal Intensive Care Unit, Puericulture Institute and Neonatal Section, University of Cagliari, Cagliari, Italy

3Department of Clinical Pharmacy and Pharmacotherapy, Heinrich-Heine University of Düsseldorf, Universitätsstrasse 1, 40225 Düsseldorf, Germany


Perinatal Pharmacology

Description

Effective and safe drug administration should be based on integrated knowledge on the evolving physiological characteristics of the patient who will receive the drug and the pharmacokinetics (PK) and pharmacodynamics (PD) of the prescribed drug. Consequently, clinical pharmacology in neonates and pregnant women is as dynamic and diverse as the patients. Mothers are exposed to drugs during pregnancy, at delivery or in postpartum, including women with comorbidity. Despite this, dosing regimens are still commonly extrapolated from regimens initially validated in adults. Infants and pregnant women warrant a focussed approach due to the physiological changes related to maturation (fetus, newborn) or pregnancy. Therefore, understanding these changes to predict exposure/effects is necessary.Modelling emerged as a promising tool to improve prediction of exposure/effects. However, these methods need further validation before implementing this approach. In addition, both effects as well as side effects may be population specific. This necessitates the validation of biomarkers (e.g., liver enzymes, renal biomarkers, and blood pressure) commonly applied in other populations, or exploration to develop, evaluate, and validate new approaches to assess drug effect or side effects (PD) in infants or pregnant women that are valid and appropriate for clinical use. Potential topics include, but are not limited to:

  • Exploration of PK/PD data in infants or pregnant women compared to other populations
  • Exploration of PK/PD data in infants or pregnant women within this specific subpopulation
  • Development and validation of PK/PD models in neonates and pregnant women. This includes also method development (allometry, physiology-based PK, and mixed effect modelling)
  • Validation of biomarkers to quantify effects or side effects in perinatal life
  • Trends in pharmacovigilance in early infancy and pregnancy
  • Pharmacoepidemiological trends in (illicit) drug exposure in perinatal life
  • Issues related to breastfeeding
  • Reports on long-term outcome, safety, and risk factors following perinatal drug exposure
  • Legal, ethical, or educational initiatives to improve study feasibility
  • Legal, ethical, or educational initiatives to improve knowledge diffusion on perinatal pharmacology

Before submission authors should carefully read over the journal’s Author Guidelines, which are located at http://www.hindawi.com/journals/bmri/guidelines/. Prospective authors should submit an electronic copy of their complete manuscript through the journal Manuscript Tracking System at http://mts.hindawi.com/submit/journals/bmri/pharmacology/pp/ according to the following timetable:


Articles

  • Special Issue
  • - Volume 2014
  • - Article ID 101620
  • - Editorial

Perinatal Pharmacology

Karel Allegaert | Vassilios Fanos | ... | Stephanie Laër
  • Special Issue
  • - Volume 2014
  • - Article ID 718769
  • - Research Article

Perinatal Hypoxia-Ischemia Reduces α7 Nicotinic Receptor Expression and Selective α7 Nicotinic Receptor Stimulation Suppresses Inflammation and Promotes Microglial Mox Phenotype

Sansan Hua | C. Joakim Ek | ... | Maria E. Johansson
  • Special Issue
  • - Volume 2014
  • - Article ID 481914
  • - Review Article

Folic Acid Supplementation and Preterm Birth: Results from Observational Studies

Elena Mantovani | Francesca Filippini | ... | Massimo Franchi
  • Special Issue
  • - Volume 2014
  • - Article ID 897216
  • - Research Article

Semiphysiological versus Empirical Modelling of the Population Pharmacokinetics of Free and Total Cefazolin during Pregnancy

J. G. Coen van Hasselt | Karel Allegaert | ... | Alwin D. R. Huitema
  • Special Issue
  • - Volume 2014
  • - Article ID 276918
  • - Review Article

Serotonin Reuptake Inhibitors in Pregnancy: Can Genes Help Us in Predicting Neonatal Adverse Outcome?

Valentina Giudici | Laura Pogliani | ... | Gian Vincenzo Zuccotti
  • Special Issue
  • - Volume 2013
  • - Article ID 892974
  • - Review Article

Sedation of Newborn Infants for the INSURE Procedure, Are We Sure?

Ellen H. M. de Kort | Irwin K. M. Reiss | Sinno H. P. Simons
  • Special Issue
  • - Volume 2013
  • - Article ID 140327
  • - Research Article

Impact of Pregnancy on Zonisamide Pharmacokinetics in Rabbits

Kamal M. Matar
  • Special Issue
  • - Volume 2013
  • - Article ID 909860
  • - Research Article

Off-Label Use of Ondansetron in Pregnancy in Western Australia

Lyn Colvin | Andrew W. Gill | ... | Carol Bower
BioMed Research International
 Journal metrics
Acceptance rate31%
Submission to final decision67 days
Acceptance to publication30 days
CiteScore3.600
Impact Factor2.276
 Submit

We are committed to sharing findings related to COVID-19 as quickly as possible. We will be providing unlimited waivers of publication charges for accepted research articles as well as case reports and case series related to COVID-19. Review articles are excluded from this waiver policy. Sign up here as a reviewer to help fast-track new submissions.